Literature DB >> 6477006

Antibiotics in patients with neutropenia.

G P Bodey.   

Abstract

Successful treatment of infection in patients with neutropenia is usually possible if several principles are followed. The most important of these is prompt administration of antibiotic therapy, even if the patient has no symptoms or signs of infection other than fever. Most infections are caused by gram-negative bacilli, but even "nonpathogenic" organisms can cause serious infections. Antibiotic combinations should be selected that provide broad-spectrum coverage and are active against the most prevalent organisms in the hospital. Aminoglycosides are often ineffective in patients with persistent neutropenia and should not be used alone. A variety of effective combination regimens are available for initial therapy of presumed or proved infection in patients with neutropenia, including a beta-lactam plus an aminoglycoside or two beta-lactam antibiotics.

Entities:  

Mesh:

Year:  1984        PMID: 6477006

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  20 in total

1.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Authors:  D Yamamura; R Gucalp; P Carlisle; M Cimino; J Roberts; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Risk assessment and risk-based therapy in febrile neutropenic patients.

Authors:  K V Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-07       Impact factor: 3.267

4.  Febrile neutropenic events in cancer patients: treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours.

Authors:  M Nobbenhuis; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.

Authors:  K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

6.  Activity of newer antimicrobial agents against Aeromonas hydrophila.

Authors:  K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

7.  Imipenem-cilastatin as initial therapy for febrile cancer patients.

Authors:  G P Bodey; M E Alvarez; P G Jones; K V Rolston; L Steelhammer; V Fainstein
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

8.  Ceftazidime does not enhance cyclosporin-A nephrotoxicity in febrile bone marrow transplantation patients.

Authors:  C Verhagen; B E de Pauw; T de Witte; R S Holdrinet; J T Janssen; K J Williams
Journal:  Blut       Date:  1986-10

9.  Gentamicin pharmacokinetics in patients with malignancies.

Authors:  J S Bertino; L A Booker; P Franck; B Rybicki
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole.

Authors:  F Menichetti; A Del Favero; R Guerciolini; M Tonato; F Aversa; F Roila; R F Frongillo; M F Martelli; S Davis; S Pauluzzi
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.